8-K: CooperCompanies Reports Q2 2026 Results Amid Litigation Charge

CooperCompanies achieved record Q2 2026 revenue of $1.082 billion, though GAAP earnings were impacted by a $271.6 million litigation-related charge.

Summary

• Reported fiscal second quarter 2026 revenue of $1.082 billion, an 8% increase year-over-year.
• GAAP diluted EPS was $(0.40), reflecting a significant litigation-related charge.
• Non-GAAP diluted EPS reached $1.21, representing a 26% increase compared to the prior year.
• CooperVision revenue grew 8% to $723.5 million, while CooperSurgical revenue grew 8% to $358.0 million.
• The company recorded a $271.6 million net pre-tax charge to resolve claims related to a December 2023 fertility media recall.
• Management reaffirmed long-term free cash flow objectives exceeding $2.2 billion for fiscal years 2026-2028.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report because the company successfully addressed a major litigation overhang while maintaining strong organic growth and operational profitability.

Positives

• Record quarterly revenue of $1.082 billion, up 8% reported and 5% organically.
• Non-GAAP diluted EPS of $1.21, up 26% year-over-year.
• Tenth consecutive quarter of exceeding consensus earnings expectations.
• Substantial resolution of over 95% of claims related to the CooperSurgical fertility media recall.
• Non-GAAP operating margin expanded 260 basis points to 27%.

Negatives

• GAAP net loss of $77.9 million for the quarter.
• GAAP operating margin fell to negative 3% from 18% in the prior year period.
• Significant $271.6 million net pre-tax charge recorded in SG&A expenses.
• Increased litigation-related liabilities of $324.1 million.

Risks

• Potential for remaining litigation claims to exceed current accruals.
• Ongoing defense and expert costs associated with remaining legal matters.
• Exposure to foreign currency exchange rate fluctuations impacting net sales.
• Risks associated with global supply chain disruptions and manufacturing operations.
• Compliance costs related to evolving EU medical device regulations.

Future Outlook

The company updated its fiscal 2026 guidance, projecting total revenue between $4.285 billion and $4.321 billion with organic growth of 3.5% to 4.5%. Non-GAAP diluted EPS is expected to be between $4.58 and $4.66.

Management Comments

• We delivered a strong second quarter, achieving record revenue and non-GAAP earnings per share while marking our tenth consecutive quarter of exceeding consensus earnings expectations.
• We have reached agreements to resolve substantially all of the outstanding claims related to CooperSurgical's fertility media recall, representing an important step in addressing this issue.
• Moving forward, we are focused on driving sustainable, profitable growth and strong cash flow, while maintaining discipline in a dynamic operating environment.

Industry Context

StockSavvy.ai notes that CooperCompanies continues to demonstrate resilience in its core medical device segments despite significant non-recurring legal headwinds. The company's ability to maintain organic growth while navigating complex product liability litigation aligns with broader trends of consolidation and operational efficiency in the medical technology sector.

Comparison to Industry Standards

• Revenue growth of 5% organically remains competitive with peers in the vision care and fertility markets.
• Non-GAAP operating margin of 27% reflects strong operational discipline compared to industry benchmarks for diversified medical device manufacturers.
• The resolution of litigation via settlement is a standard risk-mitigation strategy employed by large-cap medical device firms to remove uncertainty for investors.

Legal Proceedings

• The company resolved over 95% of claims related to the December 2023 CooperSurgical fertility media recall.
• A $271.6 million net charge was recorded to address litigation liabilities and expected insurance recoveries.

Stakeholder Impact

• Shareholders: Impacted by the one-time litigation charge on GAAP earnings, but supported by strong non-GAAP performance and reaffirmed guidance.
• Customers: The resolution of the recall issue provides stability for fertility clinic partners and patients.
• Creditors: The company maintains a solid balance sheet with sufficient liquidity to manage settlement payments.

Next Steps

• Execution of settlement payments for litigation claims during fiscal 2026.
• Continued focus on achieving fiscal 2026 revenue and EPS guidance.
• Ongoing strategic review following the resolution of the fertility media recall.

Key Dates

Recommendation

The company has effectively cleared a major legal hurdle that was weighing on the stock, while simultaneously delivering record revenue and strong non-GAAP earnings growth. The reaffirmation of full-year guidance suggests management has high confidence in the underlying business fundamentals.

Keywords

CooperCompanies, CooperVision, CooperSurgical, Medical Devices, Fertility, Contact Lenses, Earnings Report, Litigation